This study is an extended study of KSTHD\_FURESTEM-CD phase 1 / 2a clinical trials in patients with moderate active Crohn's disease who had received at least once a FURESTEM-CD injection. The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients for approximately 36 months (144 weeks).
Age
19–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients who has history of FURESTEM-CD Inj. injection at least once.
patients who understand and voluntarily sign an informed consent form.
You may not be if
any other condition which the Principle Investigator judges would make subject unsuitable for study participation.
